Roy N. Alcalay, MD
Joseph Quinn, MD
Carlos Singer, MD
The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.
The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD. Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.
This webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.
This course is intended for neurologists interested or specializing in Movement Disorders.
- Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
- Explain the current state of development of clinical trials of both therapies
- Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
- Identify future directions of these novel therapeutic modalities